The present disclosure is directed to medium chain length polyhydroxyalkanoate (mcl-PHA) copolymers, and to chewing gum bases and chewing gums comprising the mcl-PHA copolymers. In some instances, the mcl-PHA copolymers may partially or completely replace conventional petroleum-based gum base polymers, including elastomers, in the chewing gum and gum base. The chewing gums and gum bases of the present disclosure may be free or substantially free of petroleum-based ingredients. Chewing gums comprising the mcl-PHA copolymers of the present disclosure may also have enhanced degradability as compared to conventional chewing gums.

The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

The present invention relates to a Lactobacillus acidophilus KBL409 strain and uses thereof, wherein the Lactobacillus acidophilus KBL409 (deposit number KCTC 13518BP) strain according to the present invention reduces inflammation of the kidney, reduce the concentration of uremic toxins such as blood urea nitrogen, creatinine and p-cresol to protect the kidney, and thus may be usefully utilized for prophylactic and therapeutic applications of renal diseases including improving renal function and chronic renal failure.

The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

The present disclosure relates generally to formulations, compositions or foodstuff additives for use in modulating a glycemic response for treating or preventing diabetes or obesity and processes and method of its manufacture. Described is a formulation, a composition or a foodstuff for modulating a glycemic response manufactured from at least one phenylpropanoid encapsulated in a first cyclodextrin; and a second cyclodextrin. Preferably, the at least one phenylpropanoid is quercetin, phlorizin, myricetin, dihydromyricetin or any combination thereof, the first cyclodextrin is gamma cyclodextrin, and the second cyclodextrin is alpha cyclodextrin.

The present application relates to compositions corn-sing a bioactive lipophilic compound, an oil and at least one solubilizing agent that is a compound of Formula (I), to emulsions comprising such compositions and to uses thereof. The present application also relates to methods of preparing such emulsions. The methods comprise heating such compositions to form a homogeneous melt and combining the homogeneous melt with water to obtain the emulsion.

A spray dried, low-sodium, salt composition comprising a plurality of microspheres is provided, wherein said microspheres are composed of sodium chloride; a salt modulator; and a matrix polymer, and wherein said microspheres have an average particle size of less than 30 microns and have the sodium chloride distributed on the surface thereof.

One of the objects of the present invention is to provide a technique that can stabilize plant oil microparticles dispersed in a beverage even with little use of an emulsifier. This invention is characterized by using a plant oil and a silicone oil in combination.

Provided are a 4-ureido-5-carboxyl-imidazole-amide hydrolase and use thereof, particularly use in the treatment of gout.

A dietary composition and method for treating kidney damage and/or disease with a fasting-mimicking diet is provided. The method includes a step of identifying a subject having kidney damage. A low sodium fasting-mimicking diet with a specific dietary composition is administered to the subject for a first time period of 1 to 10 days.